Sanofi (SNY)
A+
Pipeline Grade
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
FEXINIDAZOLE
FEXINIDAZOLE |
APPROVED | Acute Leukemia, Acute Lymphocytic Leukaemia, Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia, Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia, Allergic Rhinitis, Alzheimer Disease, Amyotrophic Lateral Sclerosis (Healthy Volunteers), Atopic Dermatitis, Atrial Fibrillation, Bacterial Infections, Breast Cancer, Cancer of the Biliary Tract, Cancer of the Gallbladder, Cancer/Squamous Cell Carcinoma of Skin, Cerebral Malaria, Chronic Graft-versus-host-disease, Chronic Kidney Disease, Chronic Kidney Disease Stage 4, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Circulating Tumor Cells, Cold Agglutinin Disease, Colorectal Cancer, Congestive Heart Failure, COVID-19, Dengue Fever, Dengue Hemorrhagic Fever, Depressive Disorder, Dermatitis Atopic, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diphtheria, Dyslipidemia, Encephalitis, Eosinophilic Duodenitis (EoD), Eosinophilic Eso |
|
TAMSULOSIN HYDROCHLORIDE
FLOMAX |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.